Expedient synthesis of an atypical oxazolidinone compound library by Cully, Sarah J. et al.
Expedient Synthesis of an Atypical Oxazolidinone Compound Library 
 
Sarah J. Cully,a Thomas E. Storr,a Michael J. Rawling,a Induka R. Abeysena,b Daniel Hamza,c Geraint Jones,c 
Christopher A. Pearce,c Abdul Quddus,c William Lewisd and Robert A. Stockman*a 
 
a. School of Chemistry, The University of Nottingham, University Park, Nottingham NG7 2RD, UK. 
b. School of Chemistry, University of East Anglia, Norwich NR4 7TJ, UK. 
c. Sygnature Discovery, BioCity, Pennyfoot Street, Nottingham NG1 1GF, UK. 
d. X-ray Crystallography Section, School of Chemistry, The University of Nottingham, University Park, Nottingham NG7 2RD, 
UK. 
 
Abstract 
In order to address the current downturn in the drug discovery pipeline, initiatives are being 
undertaken to synthesise screening libraries of sp3-rich, low molecular weight compounds. As part of the 
European Lead Factory initiative, the synthesis and derivatisation of a simple hexahydrooxazolo[5,4-
c]pyridin-2(1H)-one bicyclic carbamate has been achieved. The synthetic route employed involved a 
telescoped hetero-Diels-Alder/[2,3]-sigmatropic rearrangement/cyclisation sequence to deliver the 
desired core scaffold containing two points for further diversification. When applied, this synthesis was 
found to be robust and scalable which allowed the production of a 155 compound library. 
 
1. Introduction 
The urgent need for drug discovery programmes to move away from identifying hit compounds 
using chemical libraries of flat, (hetero)aromatic constituents has been highlighted in a number of 
publications.1 It is accepted that flat compounds contribute to high attrition rates due to poor 
pharmacokinetic profiles and late stage toxicity studies due to off-target effects. Chiral, three-dimensional 
compounds are more likely to form complementary interactions with specific biological targets, reducing 
off-target side-effects and potentially providing ligands for more challenging targets.1 Initiatives have been 
realised which fund the compilation of new, innovative screening libraries with the aim of injecting novelty 
back into drug discovery pipelines to tackle the ensuing stalemate with regards to getting new, improved 
drugs to market.2 Advances in sp2-sp2 coupling reactions led to the creation of the current available 
libraries and so it is imperative that similar robust and facile chemistry is implemented in analogous sp3-
rich collections. Approaches to the new libraries include fragment-based screening and diversity-
orientated synthesis, often with a focus on the synthesis of sp3-rich, three-dimensional core structures.3 
The aim of the work described herein was to synthesise a small library of sp3-rich compounds based upon 
a fused oxazolidinone/piperidine ring scaffold, containing a cis-ring junction and at least two functional 
groups available for diversification. 
Carbamates are well precedented in medicinal chemistry as physiologically stable peptidomimetics 
capable of penetrating cell membranes.4 Cyclic carbamates, such as the oxazolidinones, are the most 
metabolically stable carbamates and are a widely known pharmacophore for antibacterial agents.4 
Linezolid (1, Figure 1. A) is the archetypal oxazolidonone antibiotic used for the treatment of Gram-
positive strains of methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant 
Enterococcus faecium (VRE).5 Antibacterial activity in this series usually requires substitution at the 5-
position of the oxazolidinone ring with predictable stereochemistry, as exemplified by the most well 
developed analogue of 1, tedizolid (2, Figure 1. A) which displays activity in linezolid-resistant bacteria 
and was approved, as a phosphate prodrug, in 2014 in the USA to treat acute bacterial skin infections.6 
Aside from antibacterial activity, the oxazolidinone pharmacophore is present in rivaroxaban (3, Figure 1. 
A), a factor Xa inhibitor for the treatment of deep vein thrombosis and pulmonary embolism.7  
 
It is hoped that inclusion of an oxazolidinone motif in the innovative bicycle 4 could potentially 
uncover a novel therapeutic opportunity (Figure 1. B). As an addition to our continued interest in scaffold 
synthesis, discussed herein are results pertaining to the synthesis and derivatisation of the chemical 
scaffold of the type 4.8 N-Functionalisation of the oxazolidinone ring nitrogen would provide scaffolds from 
which novel libraries of compounds could be synthesised, by further derivatisation of the piperidine ring 
nitrogen. Incorporation of nitrogen atoms as the handle for diversification is desired as this potentially 
gives access to functional groups such as amines, amides and sulfonamides through facile and high-
throughput synthetic methods. The low molecular weight (142 Da) and cLogP (-1.2) of the unsubstituted 
scaffold, render this scaffold an excellent starting point for a drug discovery programme if found to possess 
any biological activity.9 
 
 
Figure 1.  A - Known cyclic-carbamate containing pharmacophores (1-3). B - Targeted bicyclic potential 
pharmacophores 4a and 4b. 
 
There are two regioisomers of the targeted scaffold which were highlighted as potential targets; 4a 
(hexahydrooxazolo[5,4-c]pyridin-2(1H)-one) and 4b (hexahydrooxazolo[4,5-c]pyridin-2(3H)-one).  
Several routes towards the synthesis of carbamates are known in the literature; however there 
significantly fewer published syntheses of fused bicyclic oxazolidinones of this class containing a cis-ring 
junction. In order to scale the synthesis of this scaffold to produce a library of hundreds of compounds, the 
synthetic route chosen must be amenable in terms of cost, safety and expediency. Three potential syntheses 
towards intermediates 4a and 4b were identified (Scheme 1). The use of Du Bois’ Rh-catalysed C-H 
insertion chemistry of a carbamate such as 5,10 a Trost-type Pd-catalysed reaction of a vinyl epoxide (6) 
and isocyanate,11 which would both give rise to regioisomer 4b, and finally Weinreb’s metal-free allylic 
sulfoxide route which would give alternative regiochemistry seen in 4a (Scheme 1).12 
 
 
Scheme 1. Retrosynthetic analysis towards the synthesis of scaffold 4. 
 
2. Results and Discussion 
Our initial investigations focussed upon applying the two transition metal-catalysed routes to 
generate cores of the general structure 4a. The Du Bois method was initially attempted with a number of 
appropriate carbamates (5), which were subjected to typical literature conditions for the C-H insertion 
reaction.10 Unfortunately, the cyclised products 4 were not observed in appreciable quantities (Scheme 2). 
However, the palladium catalysed method for the generation of intermediate 7c, a precursor to 4a, was 
applied with more success. The relevant epoxide 6 was subjected to reaction with a small range of 
isocyanates.9 Both the N-4-methoxyphenyl and N-4-toluenesulfonate protected intermediates 7a and 7b 
were synthesised in 64% and 36% yields respectively and could both be deprotected to provide 7c. Despite 
this protocol being productive, reproducibility, purification and scalability issues caused by complex 
reaction mixtures were experienced. These problems forced us to abandon the use of this regioisomer in 
the remainder of the synthesis.     
 
 Scheme 2. Ineffective routes towards target core 4a. Representative conditions: i - Rh2(OAc)4, PhI(OAc)2, 
MgO, CH2Cl2, 40 °C, 36 h. ii - Pd2(dba)3.CHCl3, P(OiPr)3, CH2Cl2, R2NCO, RT, 18 h. iii - CAN, MeCN, 2 h, RT. iv 
- naphthalene, Na, DME, THF, -78 °C-RT, 18 h. 
 
With these preliminary set-backs, the work then shifted to focus on a low cost, expedient synthesis 
of relevant intermediates which did not necessitate the use of expensive transition metal-catalysts at an 
early stage in the synthesis. A diastereoselective synthesis of 7d (regioisomer of 7c) was identified, which 
had previously been utilised in the synthesis of marine sponge alkaloid agelastatin A by Weinreb et al. 
(Scheme 3).12b  Synthesis of sulfinyl carbamate 9 proceeded well as per the literature from thionyl chloride 
addition to O-methyl carbamate (8).13 We found that, in agreement with Whitesell et al., handling the 
reaction mixture and product under strict anaerobic conditions gave optimal yields on multigram scale of 
this reportedly capricious reaction.14 The one-pot Diels-Alder cycloaddition of sulfinyl carabamate 9 with 
cyclopentadiene and subsequent ring-opening of the unstable product with phenyl Grignard gave allylic 
sulfoxide 10 in 48% yield. Literature precedent demonstrates that the desired oxazolidinone 7d can be 
obtained in two steps from 10.15 A thermal [2,3]-sigmatropic rearrangement to the corresponding 
sulfonate ester, followed by treatment of the rearranged product with HMPT facilitates ring closure to 
deliver 7d. Use of toxic HMPT on scale was a health and safety concern, hence, after an assessment of a 
variety of phosphorus(III) reagents, it was found that trimethyl phosphite provided the key intermediate 
(7d) in a moderate yield of 61% over 2 steps (Scheme 3). 
 
 
Scheme 3. Synthesis of 7d via an allylic sulfoxide rearrangement. i - SOCl2, Py, Et2O, RT, 3 h. ii - 
cyclopentadiene, PhH, RT, 24 h. iii - PhMgBr, THF, RT, 20 min. iv - P(OMe)3, EtOH, Δ, 36 h. v - KOH, MeOH, 
RT, 24 h. 
 
With key intermediate 7d in hand, functionalisation of the carbamate nitrogen could be performed 
to provide the library precursors (Scheme 4). Treatment with nBuLi at -78 °C followed by the addition of 
the relevant electrophile provided the N-ethyl, 4-bromobenzyl, acetyl and 4-toluenesulfonyl bearing 
derivatives (11a-d) in good yields (66-85%; Scheme 4).  Each derivative was subjected to a one-pot 
oxidative cleavage of the olefin under ozonolysis conditions followed by reductive amination of the 
intermediate ozonide with a small range of amines (Scheme 4, Table 1).   
 
 
Scheme 4. N-Functionalisation and ring expansion of 7d. i - nBuLi, R1X, THF, -78 °C (X = I for 11a, Br for 
11b and Cl for 11c and 11d). ii - O3, MeOH, -78 °C. iii - NaBH3CN, R2NH2, 0 °C.  
 
Table 1. Synthesis of piperidines 12a-d. 
Entry SM R1 R2 Yield (%) Prod. 
1 
11a 
Et 4-Br(C6H4)CH2 37 12a 
2 Et Me 25 12b 
3 Et tBu 0 - 
4 
11b 
4-Br(C6H4)CH2 4-Br(C6H4)CH2 55 12c 
5 4-Br(C6H4)CH2 Me 29 12d 
6 11c Ac 4-Br(C6H4)CH2 0 - 
7 11d Ts Bn 91 13 
1 – By-product derived from the hydrolysis of the desired product. 
 
Ring-expansion of N-ethyl scaffold 11a was successful with two of three attempted amines, with 
tert-butylamine being too sterically hindered to succeed (Table 1, Entries 1-3). Similarly, the 
bromobenzylamine furnished substrate (11b) ring expansion proceeded well for two attempted amines 
(Table 1, Entries 4 and 5). We found the acetyl and 4-toluenesulfonyl functionalities were ineffective at 
generating the desired products under the ozonolysis reaction conditions; indeed, a side-product (13) was 
isolated from the reaction where R1 = 4-toluenesulfonyl. Compound 13 was identified as a product of 
hydrolysis (due to the basic work-up) of the carbamate ring post ring expansion (Table 1, Entry 7). A single 
crystal X-ray structure of this product (13) was determined which provides evidence to support the cis-
configuration of the ring junction in compounds 12a-l (Figure 2).   
 
    
Figure 2. X-ray diffraction crystal structure of hydrolysis product (13) showing cis-configuration of C3 
hydroxyl and C4 sulfonamide functionalities. 
 
The synthetic route outlined in Scheme 4 demonstrated the facile nature by which carbamate 
functionalisation and N-alkyl piperidine generation can be performed. However, to improve the synthetic 
utility of the reaction sequence and therefore increase the potential diversity of the intended library, an 
orthogonal synthetic route was developed (Scheme 5). Unsubstituted intermediate 7d was subjected to 
oxidative cleavage/reductive amination of the olefin with benzylamine to give the benzyl-protected 
piperidine 12e.  N-Functionalisation of the carbamate nitrogen can then be performed as exemplified by 
the synthesis of N-ethylated compound 12f. Removal of the piperidine benzyl protecting group under 
acidic hydrogenolysis conditions allowed access to the secondary amines 14 and 15. From these cores, a 
small exemplary compound library of 6 compounds (12g-l) was produced via standard amidation and 
reductive amination reactions (Scheme 5, Table 2). Both of these protocols are highly amenable to plated 
library synthesis allowing for the potential of rapid library synthesis. 
 
 
Scheme 5. Alternative route to the synthesis of library compounds (12) from 7d. i - O3, MeOH, -78 °C. ii - 
NaBH3CN, BnNH2, 0 °C. iii – H2 (1 atm.), Pd/C, HCl, MeOH, RT, 18 h. iv - nBuLi, EtI, THF, -78 °C. 
 
 
 
 
Table 2. Examples of piperidine N-functionalisation library steps. 
Entry SM R1 R2 Yield (%) Prod. 
11 14 H 
 
27 12g 
21 15 Et 67 12h 
31 14 H 
 
30 12i 
41 15 Et 47 12j 
52 14 
H 
 
55 12k 
62 14 
 
67 12l 
1 – R2CO2H, HATU, NEtiPr2, DMF, RT, 18 h. 2 – R2CHO, AcOH, NaHB(OAc)3, NMP, RT, 18 h. 
 
Each library compound synthesised was found to be chemically stable in DMSO (one week, ambient 
temperature, in sunlight) and consequently validated the carbamate/piperidine scaffold as a viable library 
structure. To this end, a proof of principle library of 155 unique compounds was synthesised; these have 
subsequently been added to the Joint European Compound Library (JECL).16 Exemplary property data of 
the produced library is presented in Figure 3 which demonstrates the range and diversity of this 
compound family. 
 
 
Figure 3. A – Chart of CLogP versus MW for a library of 155 compounds based on scaffold 4a. B – Chart of 
demonstrating the distribution of compounds synthesised and their respective Fsp3. 
 
3. Conclusions 
A low cost, expedient synthesis of a potential pharamacophore has been demonstrated. The 
innovative cis-fused oxazolidinone/piperidine ring system was synthesised in four synthetic steps from 
commercially available O-methyl carbamate. The use of an ozonolysis/reductive amination protocol 
enabled the rapid generation of a desired piperidine ring. Further to this, N-functionalisation of the 
carbamate nitrogen was demonstrated to be a facile process, which provided a number of scaffolds for 
further diversification on the piperidine ring nitrogen. The synthetic route described has provided a 
synthetic sequence that has enabled the synthesis of a library of compounds of the general structure 4a. 
Importantly, a number of chemically stable library compounds, with appealing lipophilicity and molecular 
weight properties, were synthesised currently constitute a part of the openly accessible JECL for lead 
generation for both academia and industry.   
 
4. Experimental  
 
4.1 General experimental details 
Nuclear Magnetic Resonance (NMR) spectra were recorded on a 400 (Bruker® DPX400, AV400, or 
AVIII400) NMR spectrometers in CDCl3 or DMSO-d6 at 300 K (unless stated otherwise). All spectra were 
referenced to the residual hydrogen solvent peaks for 1H NMR (CDCl3 δ = 7.26 ppm, DMSO-d6 = 2.50) and 
the solvent peak for 13C NMR (CDCl3 δ = 77.0 ppm, DMSO-d6 = 39.5). NMR Chemical shifts (δ) are reported 
in ppm; coupling constants (J) are reported in Hz; splitting patterns are assigned s = singlet, d = doublet, t 
= triplet, q = quartet, br = broad signal; and app = the apparent multiplicity. High resolution mass 
spectrometry (HRMS) data was obtained using a Bruker® MicroTOF spectrometer measured using 
electrospray ionization (ESI).  Infrared spectroscopic data were recorded using a Bruker® Tensor27 FTIR 
spectrometer.  Melting points were measured on a Stuart Scientific SMP3 apparatus and are uncorrected. 
Solvents, unless otherwise stated, were purchased in reagent grade or anhydrous quality and used as 
received. THF was distilled from Na/benzophenone immediately prior to use and diethyl ether was 
obtained from in-house purification towers. Reagents were either purchased directly from commercial 
suppliers or prepared according to literature procedures.  Reactions were monitored using aluminium 
backed silica thin layer chromatography with a fluorescent dye (λ = 254 nm) and visualised under UV 
illumination or staining with basic KMnO4 dye.  Flash column chromatography was performed manually 
on silica gel (Fluka 60) with pressurised air flow (except where stated otherwise). 
 
4.2 Procedure for the synthesis of compound 10 
To a solution of methyl carbamate (20.0 g, 266 mmol) in diethyl ether (300 ml) was added SOCl2 (21.0 mL, 
288 mmol) at 0 °C, after stirring for 5 min the reaction mixture was allowed to warm to RT and stirred for 
a further 30 min. A solution of pyridine (40.9 mL, 506 mmol) in diethyl ether (60.0 mL) was added slowly 
over 1.5 h and then stirred for further 1.5 h. The resulting precipitate was filtered under N2. The filtrate 
was concentrated in vacuo to give 9 (32.0 g, 264 mmol, Quant.) as yellow oil. The material was used without 
any further purification [1H NMR (400 MHz, CDCl3) δ 3.94 (3H, s, CH3)]. To a solution of methyl 
sulfinylcarbamate (9, 10.0 g, 83 mmol) in benzene (60.0 mL) was added freshly distilled cyclopentadiene 
(9.7 mL, 116 mmol) dropwise and the resulting solution was stirred for 20 h at RT.  The solution was 
diluted with THF (110 mL) and phenylmagnesium bromide (1 M in THF, 83.0 mL, 83 mmol) was added 
over 45 min then stirred for 30 min before being quenched by addition of sat. aq. NH4Cl (100 mL).  
Extracted with EtOAc (3 x 100 mL), combined organic phases were washed with brine (100 mL), dried 
(MgSO4) and concentrated in vacuo. Purification (MPLC, Si, EtOAc/petrol, 80%) gave 10 as mixture of 
diastereomers in approx. 85% purity, which was used in the subsequent reaction (10.4 g, thick oil,  
estimated 48% yield taking into account small impurities). 
 
4.2.1 Compound 1012b 
Orange coloured oil. Rf = 0.72 (EtOAc); IR cm-1 3011, 2360, 2341, 1716, 1516; 1H NMR (400 MHz, 
CDCl3) δ 7.57-7.47 (5H, m, H-Ar), 6.17-5.99 (2H, m, H-2 and H-3), 5.83 (1H, d, J = 8.8 Hz, NH), 4.78 (1H, dd, 
J = 8.8 and 8.7 Hz, H-1), 3.84-3.78 (1H, m, H-4), 3.68 (3H, s, CH3), 2.17 (1H, ddd, J = 15.3, 8.7 and 8.5 Hz, H-
5), 1.78-1.73 (1H, m, H-5); 13C NMR (100 MHz, CDCl3) 171.1 (CO2Me), 156.3 (C-Ar), 142.0 (C-2 or C-3), 130.9 
(C-Ar), 129.3 (C-Ar), 129.1 (C-Ar), 128.0 (C-2 or C-3), 124.0 (C-Ar), 71.2 (C-4), 53.4 (C-1), 52.0 (CH3), 29.2 
(C-5); HRMS ESI+ m/z C13H15NO3S calculated: 288.0665 [M+Na]+, found: 288.0654. 
 
4.3 Procedure for the synthesis of 7d 
To a solution of methyl (Z)-(5-(phenylsulfinyl)hex-3-en-2-yl)carbamate  (10, 39.7 g, 135 mmol) in 
ethanol (200 mL) was added trimethyl phosphite (17.5 mL, 148 mmol) and the reaction heated to 80 °C 
for 36 h before the solvent was removed in vacuo. The crude mixture was stirred in a 10% solution of KOH 
in MeOH (100 mL) for 2 h. The mixture was then acidified by addition of 1 M HCl (250 mL) then extracted 
with EtOAc (4 x 200 mL). The combined organic phase was washed with brine (200 mL), dried (MgSO4) 
and solvent removed in vacuo. Purification (MPLC, Si, EtOAc/isohexane 0-100%) followed by trituration 
with diethyl ether gave 7d (2.9 g, 17% yield) as a white solid. The aqueous was concentrated in vacuo and 
the resulting solid was suspended in EtOAc (500 mL) and slurried for 1 h before filtering. The filtrate was 
concentrated in vacuo and then triturated with diethyl ether to give combined 7d (10.2 g, 61%). 
 
4.3.1 Compound 7d12b 
A white solid.  Rf = 0.63 (EtOAc 100%); M.p. 120-122 °C; IR cm-1 3468, 3011, 1750; 1H NMR (400 
MHz, CDCl3) δ 6.08-6.06 (1H, m, H-alkene), 5.89-5.85 (1H, m, H-alkene), 5.62 (1H, br s, NH), 5.58-5.55 (1H, 
m, H-5), 4.47-4.43 (1H, m, H-1), 2.76-2.68 (1H, m, H-2), 2.54-2.47 (1H, m, H-2); 13C NMR (101 MHz, CDCl3) 
δ 158.9 (CO), 135.3 (C-3 or 4), 128.5 (C-3 or 4), 86.2 (C-5), 53.3 (C-1), 40.7 (C-2); HRMS m/z C6H7NO2 
calculated: 148.0369 [M+Na]+, found: 148.0366. 
 
4.4 General procedure for functionalisation cyclic carbamates using nBuLi 
To a solution of 7d (1 mol. equiv.) in THF (1 mL/0.5 mmol) at -78 °C was added nBuLi (2.5 M in 
hexanes, 1.1 mol. equiv.) and stirred for 30 min before a solution of the appropriate halide (1.2 mol. equiv.) 
in THF (1 mL/0.5 mmol) was added dropwise.  The solution was allowed to warm to RT overnight then 
heated to 70 °C for 12 h.  Brine was added and extracted with EtOAc (3 x 1 mL/0.3 mmol), dried (MgSO4) 
and concentrated in vacuo.  
 
4.4.1 Compound 11a 
Compound 11a was prepared according to the general procedure (4.4): 7d (200 mg, 1.6 mmol), 
THF (3.0 mL), nBuLi (2.5 M in hexanes, 0.7 mL, 1.8 mmol) and iodoethane (0.15 mL, 1.9 mmol) in THF (3.0 
mL).  Purification (MPLC, Si, EtOAc/petrol 60%) gave 11a (160 mg, 66%) as a yellow oil. Rf = 0.33 
(EtOAC/petrol 50%); IR cm-1 3011, 2983, 2938, 1737; 1H NMR (400 MHz, CDCl3) δ 6.08-6.06 (1H, m, H-3), 
5.86 (1H, dd app.t, J = 5.9, 2.2 and 2.1 Hz, H-4), 5.43-5.40 (1H, m, H-5), 4.39 (1H, ddd, J = 7.9, 5.9 and 2.0 Hz, 
H-1), 3.58 (1H, dt, J = 14.8 and 7.5 Hz, CHHCH3), 3.05 (1H, dt, J = 14.5 and 7.2 Hz, CHHCH3), 2.63-2.49 (2H, 
m, H-2), 1.18 (3H, t, J = 7.4 Hz, CH3); 13CNMR (101 MHz, CDCl3) δ 157.0 (CO), 135.0 (C-3 or 4), 128.7 (C-3 or 
4), 82.4 (C-5), 56.1 (C-1), 37.4 (C-2), 37.3 (CH2CH3), 12.4 (CH3); HRMS m/z calculated for C8H12N1O2: 
154.0863 [M+H]+, found: 154.0861. 
 
4.4.2 Compound 11b 
Compound 11b was prepared according to the general procedure (4.4): 7d (200 mg, 1.6 mmol), 
THF (3.0 mL), nBuLi (2.5 M in hexanes, 0.7 mL, 1.8 mmol) and 4-bromobenzylbromide (475 mg, 1.9 mmol) 
in THF (3.0 mL).  Purification (MPLC, Si, EtOAc/petrol 40%) gave 11b (378 mg, 80%) as a yellow oil. Rf = 
0.64 (EtOAc/petrol 50%); IR cm-1 3011, 2933, 1739; 1H NMR (400 MHz, CDCl3) δ 7.48 (2H, d, J = 8.4 Hz, H-
Ar), 7.17 (2H, d, J = 8.4 Hz, H-Ar), 6.04-6.01 (1H, m, H-4), 5.87 (1H, ddd, J = 6.0, 2.2 and 2.1 Hz, H-3), 5.39-
5.35 (1H, m, H-5), 4.68 (1H, d, J = 15.3 Hz, H-benzylic), 4.13 (1H, ddd, J = 7.9, 3.2 and 3.1 Hz, H-1), 4.07 (1H, 
d, J = 15.3 Hz, H-benzylic), 2.48-2.46 (2H, m, H-2); 13C NMR (101 MHz, CDCl3) δ 157.4 (CO), 135.1 (C-3 or 
C-4), 135.0 (C-3 or C-4), 132.0 (C-Ar), 130.0 (C-Ar), 128.7 (C-Ar), 122.0 (C-Ar), 82.8 (C-5), 56.3 (C-1), 46.3 
(C-benzylic), 36.9 (C-2); HRMS m/z calculated for C13H12BrNO2: 294.0124 [M+H]+, found: 294.0115. 
 
4.4.3 Compound 11c 
Compound 11c was prepared according to the general procedure (4.4): 7d (200 mg, 1.6 mmol), 
THF (3.0 mL), nBuLi (2.5 M in hexanes, 0.7 mL, 1.8 mmol) and acetyl chloride (0.14 mL, 1.9 mmol) in THF 
(3.0 mL).  Purification (MPLC, Si, EtOAc/petrol 40%) gave 11c (272 mg, quantitative) as a pale orange oil. 
Rf = 0.69 (EtOAc/petrol 50%); 1H NMR (400 MHz, CDCl3) δ 6.14 (1H, m, H-4), 5.87 (1H, app dq, J = 6.3, 2.2 
Hz, H-3), 5.45 (1H, app dt, J = 8.1, 2.1 Hz, H-5), 4.83 (1H, app td, J = 7.6, 2.1 Hz, H-1), 2.95 (1H, ddt, J = 18.7, 
7.2, 2.4 Hz, H-2a), 2.58 (1H, dm, J = 18.7, 2.3 Hz, H-2b), 2.51 (s, 3H); 13C NMR (101 MHz, CDCl3) δ 170.7 (CO), 
153.4 (CO-Ac), 137.6 (C4), 127.3 (C-3), 82.4 (C-5), 55.6 (C-1), 40.0 (C2), 23.8 (CH3); HRMS m/z calculated 
for C8H11NO3: 168.0655 [M+H]+, found: 168.0655. 
 
4.4.4 Compound 11d 
Compound 11d was prepared according to the general procedure (4.4): 7d (200 mg, 1.6 mmol), 
THF (3.0 mL), nBuLi (2.5 M in hexanes, 0.7 mL, 1.8 mmol) and 4-toluenesulfonyl chloride (362 mg, 1.9 
mmol) in THF (3.0 mL) to give 11d (376 mg, 85%) as an orange coloured solid, used without further 
purification. Rf = 0.16 (EtOAc 100%); M.p. 112-114 °C; IR cm-1 3631, 3011, 2945, 2839, 2360, 1777, 1602; 
1H NMR (400 MHz, CDCl3) δ 7.95 (2H, d, J = 8.5 Hz, H-Ar), 7.35 (2H, d, J = 8.5 Hz, H-Ar), 6.15-6.12 (1H, m, H-
4), 5.83 (1H, ddd, J = 6.1, 4.3  and 2.2 Hz, H-3), 5.44-5.40 (1H, m, H-5), 4.87 (1H, app. dt, J = 8.5 and 4.3 Hz, 
H-1), 2.98-2.95 (2H, m, H-2), 2.45 (3H, s, CH3); 13C NMR (101 MHz, CDCl3) δ 151.9 (CO), 145.7 (C-Ar), 137.1 
(C-4), 134.7 (C-Ar), 129.8 (C-Ar), 128.5 (C-Ar), 127.2 (C-3), 83.4 (C-5), 58.0 (C-1), 40.5 (C-2), 21.8 (CH3); 
HRMS m/z calculated for C13H13NO4S: 280.0638 [M+H]+, found: 280.0637. 
 
4.4.5 Compound 12f 
Compound 12f was prepared according to the general procedure (4.4): 12e (500 mg, 2.2 mmol), 
THF (6.0 mL), nBuLi (2.5 M in hexanes, 1.0 mL, 2.5 mmol) and iodoethane (0.21 mL, 2.6 mmol) in THF (6.0 
mL). Purification (MPLC, Si, EtOAC/petrol, 60%) gave 12f (312 mg, 55%) as a colourless oil.  Rf = 0.32 
(EtOAc/petrol 50%); IR cm-1 3631, 3469, 3011, 2945, 2839, 1744, 1603; 1H NMR (400 MHz, CDCl3) δ 7.38-
7.24 (5H, m, H-Ar), 4.50 (1H, d app. t, J = 6.6 and 5.5 Hz, H-7), 3.80 (1H, d app. t, J = 6.6 and 5.0 Hz, H-2), 
3.54 (2H, s, CH2 benzylic), 3.50 (1H, dq, J = 14.3 and 7.2 Hz, CHHCH3), 3.09 (1H, dq, J = 14.3 and 7.2 Hz, 
CHHCH3), 2.83 (1H, dd, J = 12.3 and 5.5 Hz, H-6), 2.54 (1H, dd, J = 12.3 and 6.7 Hz, H-6), 2.44-2.43 (2H, m, 
H-4), 2.00-1.82 (2H, m, H-3), 1.15 (3H, t, J = 7.2 Hz, CH3); 13C NMR (100 MHz, CDCl3) δ 158.5 (C=O), 137.7 
(C-Ar), 128.9 (C-Ar), 128.4 (C-Ar), 127.3 (C-Ar), 71.4 (C-7), 62.5 (CH2 benzylic), 54.1 (C-6), 52.1 (C-2), 48.1 
(C-4), 36.3 (C-CH2CH3), 25.7 (C-3), 12.6 (C-CH3); HRMS m/z calculated for C15H21N2O2: 261.598 [M+H]+, 
found: 261.601. 
 
4.5 General procedure for one-pot ozonolysis and reductive amination 
A solution of the appropriate alkene (1 mol. equiv.) in CH2Cl2/MeOH (1:1 0.34 mL/mmol) at -78 °C 
was treated with ozone until a colour change was observed to blue.  After 10 min, O2 was bubbled through 
the solution until the solution was colourless then the flask was flushed with N2.  NaCNBH3 (2.5 mol. equiv.) 
was added and stirred at -78 °C for 30 min before a solution of the appropriate amine (1 mol. equiv.) in 
MeOH (1.0 mL/mmol) was added dropwise at 0 °C and the mixture was allowed to warm to RT overnight.  
AcOH (7.5 mol. equiv.) was added and stirred for 1 h before the solution was concentrated in vacuo.  The 
residue was dissolved in CH2Cl2 (15 mL/mmol), washed with sat. aq. NaHCO3 (15.0 mL/mmol), brine, dried 
(MgSO4) and concentrated in vacuo. 
 
4.5.1 Compound 12a 
Compound 12a was prepared according to the general procedure (4.5): 11a (50 mg, 0.33 mmol) in 
CH2Cl2/MeOH (2.0 mL/ 2.0 mL) followed by NaCNBH3 (52 mg, 0.82 mmol) and 4-bromobenzylamine.HCl 
(69 mg, 0.31 mmol) in MeOH (0.3 mL).  Purification (MPLC, Si, EtOAC/petrol, 50%) gave 12a (41 g, 37%) 
as a pale yellow coloured oil.  Rf = 0.42 (EtOAc/petrol 50%); 1H NMR (400 MHz, CDCl3) δ 7.43 (2H, d, J = 8.5 
Hz, H-Ar), 7.18 (2H, d, J = 8.5 Hz, H-Ar), 4.48 (1H, dd, J = 12.1 and 6.5 Hz, H-5), 3.78 (1H, dd, J = 12.1 and 5.0 
Hz, H-1), 3.53-3.44 (3H, m, H-benzylic and CHHCH3), 3.07 (1H, dq, J = 14.0 and 7.4 Hz, CHHCH3), 2.78 (1H, 
dd, J = 12.3 and 5.4 Hz, H-4), 2.54 (1H, dd, J = 12.3 and 6.5 Hz, H-4), 2.38-2.30 (2H, m, H-3), 1.98-1.80 (2H, 
m, H-2), 1.14 (3H, t, J = 7.4 Hz, CH3); 13C NMR (101 MHz, CDCl3) δ 158.4 (C=O), 136.8 (C-Ar), 131.5 (C-Ar), 
130.5 (C-Ar), 121.1 (C-Ar), 71.3 (C-5), 61.7 (C-benzylic), 54.0 (C-4), 52.1 (C-1), 47.9 (C-3), 36.5 (C-CH2CH3), 
25.7 (C-2), 12.7 (CH3); HRMS m/z calculated for C15H19BrN2O2: 339.0703 [M+H]+, found: 339.0700. 
 
4.5.2 Compound 12b 
Compound 12b was prepared according to the general procedure (4.5): 11a (50 mg, 0.33 mmol) in 
CH2Cl2/MeOH (2.0 mL/ 2.0 mL) followed by NaCNBH3 (52 mg, 0.82 mmol) and methylamine.HCl (21 mg, 
0.31 mmol) in MeOH (0.3 mL). Purification (MPLC, Si, MeOH/EtOAC, 15%) gave 12b (15 g, 25%) as a pale 
orange coloured oil.  Rf = 0.41 (MeOH/EtOAc 10%); IR cm-1 2949, 2806, 1747, 1668; 1H NMR (400 MHz, 
DMSO-d6) δ 4.46 (1H, dd, J = 11.9 and 5.6 Hz, H-5), 3.76 (1H, dd, J = 11.9 and 6.0 Hz, H-1), 3.31-3.22 (1H, m, 
CHHCH3), 3.01 (1H, dq, J = 14.1 and 7.1 Hz, CHHCH3), 2.55 (1H, dd, J = 12.4 and 4.8 Hz, H-4), 2.39 (1H, dd, J 
= 12.4 and 5.6 Hz, H-4), 2.28-2.22 (1H, m, H-3), 2.18-2.12 (4H, m, H-3 and H-6), 1.94-1.86 (1H, m, H-2), 
1.69-1.61 (1H, m, H-2), 1.04 (3H, t, J = 7.1 Hz, CH2CH3); 13C NMR (101 MHz, CDCl3) δ 158.4 (CO), 71.1 (C-5), 
56.1 (C-4), 51.4 (C-1 or C-3), 50.3 (C-1 or C-3), 46.0 (CH2CH3), 36.4, 25.6, 12.6 (CH2CH3); HRMS m/z 
calculated for C9H16N2O2: 185.1285 [M+H]+, found: 185.1284. 
 
4.5.3 Compound 12c 
Compound 12c was prepared according to the general procedure (4.5): 11b (100 mg, 0.34 mmol) 
in CH2Cl2/MeOH (3.0 mL/ 3.0 mL) followed by NaCNBH3 (53 mg, 0.82 mmol) and 4-bromobenzylamine.HCl 
(72 mg, 0.32 mmol) in MeOH (0.5 mL). Purification (MPLC, Si, EtOAc/petrol, 80%) gave 12c (91 mg, 55%) 
as a colourless sticky solid.  Rf = 0.22 (EtOAc/petrol 50%); IR cm-1 2360, 2342, 1750; 1H NMR (400 MHz, 
CDCl3) δ 7.48-7.42 (4H, m, H-Ar), 7.18-7.14 (4H, m, H-Ar), 4.63 (1H, d, J = 15.4 Hz, H- benzylic), 4.48 (1H, 
app. dd, J = 12.0 and 6.5 Hz, H-5), 4.09 (1H, d, J = 15.4 Hz, H- benzylic), 3.60 (1H, app. dd, J = 5.1 and 12.0 
Hz, H-1), 3.46 (2H, s, H-benzylic), 2.77 (1H, dd, J = 12.4 and 5.2 Hz, H-4), 2.57 (1H, dd, J = 12.4 and 6.5 Hz, 
H-4), 2.29-2.22 (2H, m, H-3), 1.86-1.74 (2H, m, H-2); 13C NMR (101 MHz, CDCl3) δ 158.9 (CO), 136.5 (C-Ar), 
135.0 (C-Ar), 131.9 (C-Ar), 131.5 (C-Ar), 130.5 (C-Ar), 129.9 (C-Ar), 121.9 (C-Ar), 121.2 (C-Ar), 71.7 (C-5), 
61.6 (C-benzylic), 53.9, 52.2, 47.8, 45.5, 25.4 (C-2); HRMS m/z calculated for C20H20Br2N2O2: 478.9964 
[M+H]+, found: 478.9967. 
 
4.5.4 Compound 12d 
Compound 12d was prepared according to the general procedure (4.5): 11b (100 mg, 0.34 mmol) 
in CH2Cl2/MeOH (3.0 mL/ 3.0 mL) followed by NaCNBH3 (53 mg, 0.82 mmol) and methylamine.HCl (22 mg, 
0.32 mmol) in MeOH (0.5 mL). Purification (MPLC, Si, MeOH/EtOAc, 10%) gave 12d (32 mg, 29%) as a 
colourless oil.  Rf = 0.35 (EtOAc 100%); 1H NMR (400 MHz, CDCl3) δ 7.46 (2H, d, J = 8.5 Hz, H-Ar), 7.17 (2H, 
d, J = 8.5 Hz, H-Ar), 4.64 (1H, d, J = 15.4 Hz, H-benzylic), 4.52 (1H, app. dd, J = 12.1 and 6.7 Hz, H-5), 4.08 
(1H, d, J = 15.4 Hz, H-benzylic), 3.56 (1H, app. dd, J = 12.1 and 5.2 Hz, H-1), 2.78 (1H, dd, J = 12.4 and 5.4 Hz, 
H-4), 2.49 (1H, dd, J = 12.4 and 6.7 Hz, H-4), 2.33-2.19 (5H, m, H-3 and CH3), 1.93-1.77 (2H, m, H-2); 13C 
NMR (101 MHz, CDCl3) δ 158.7 (CO), 135.0 (C-Ar), 132.0 (C-Ar), 129.9 (C-Ar), 122.0 (C-Ar), 71.3 (C-5), 55.9 
(C-4), 51.4, 50.1, 45.8, 45.5, 25.2 (C-2); HRMS m/z calculated for C14H17BrN2O2: 325.0546 [M+H]+, found: 
325.0536. 
 
4.5.5 Compound 12e 
Compound 12e was prepared according to the general procedure (4.5): 7a (5.3 g, 42 mmol) in 
CH2Cl2/MeOH (50.0 mL/ 50.0 mL) (NB: colour change to green), followed by NaCNBH3 (8.0 g, 127 mmol) 
and benzylamine (4.6 mL, 42 mmol) in MeOH (5.0 mL). The crude product was purified (MPLC, Si, 
EtOAc/isohexane 0-80%). Isocyanate, polymer bound 2% DVB, 200-400 mesh (5.0 g) was added into a 
solution of 12e in CH2Cl2 (100 mL) and stirred gently at RT overnight. The suspension was filtered and the 
filtrate was conc. in vacuo to 12e (3.1 g, 32% yield) as pale yellow gum. Rf = 0.32 (EtOAc/petrol, 75%); IR 
cm-1 3448, 3009, 2953, 2820, 1760; 1H NMR (400 MHz, CDCl3) δ 7.36-7.25 (5H, m, H-Ar), 5.51 (1H, s, NH), 
4.59 (1H, d app. t, J = 6.3 and 5.4 Hz, H-7), 3.91 (1H, app. q, J = 5.4 Hz, H-2), 3.55 (2H, s, CH2 benzylic) 2.79 
(1H, dd, J = 12.2 and 5.3 Hz, H-6), 2.67 (1H, dd, J = 12.2 and 6.2 Hz, H-6), 2.51-2.32 (2H, m, H-4), 2.00-1.79 
(2H, m, H-3); 13C NMR (100 MHz, CDCl3) δ 160.1 (C=O), 137.6 (C-Ar), 129.0 (C-Ar), 128.4 (C-Ar), 127.3 (C-
Ar), 74.2 (C-7), 62.4 (C-CH2 benzylic), 53.7 (C-6), 50.0 (C-2), 47.9 (C-4), 28.3 (C-3); HRMS m/z calculated 
for C13H17N2O2 [M+H]+: 223.1285, found: 223.1279. 
 
4.5.6 Compound 13 
 Compound 13 was prepared according to the general procedure (4.5): 11d (350 mg, 1.3 mmol) in 
CH2Cl2/MeOH (12.0 mL/ 12.0 mL) followed by NaCNBH3 (195 mg, 3.1 mmol) and benzylamine (0.13 mL, 
1.2 mmol) in MeOH (0.5 mL). Purification (MPLC, Si, EtOAc/petrol, 80%) gave 13 (42 mg, 9%) as a pale 
yellow solid. Rf = 0.47 (EtOAc/petrol, 60%); M.p. 117-119 °C; IR cm-1 3379, 2929, 2854, 1768; 1H NMR (400 
MHz, CDCl3) δ 7.79 (2H, d, J = 8.3 Hz, H-Ar), 7.33-7.24 (7H, m, H-Ar), 5.12 (1H, d, J = 9.0 Hz, OH), 3.54-3.46 
(3H, m, H-benzylic, H-5), 3.27-3.20 (1H, m, H-1), 2.91-2.75 (2H, m, H-4, H-3), 2.44 (3H, s, CH3), 2.14-1.97 
(2H, m, H-4, H-3), 1.72-1.67 (2H, m, H-2); 13C NMR (101 MHz, CDCl3) δ 143.3 (C-Ar), 138.7 (C-Ar), 137.6 (C-
Ar), 129.8 (C-Ar), 129.0 (C-Ar), 128.4 (C-Ar), 127.4 (C-Ar), 126.9 (C-Ar), 67.2 (C-5), 62.1 (C-benzylic), 58.0 
(C-4), 53.4 (C-1), 51.7 (C-3), 28.3 (C-2), 21.5 (CH3); HRMS m/z calculated for C19H24N2O3S: 361.1580 [M+H]+, 
found: 361.1583. 
 
4.6 Procedure for the synthesis of compound 14.HCl 
To a solution of 12e (400 mg, 1.7 mmol) in MeOH (15.0 mL) was added HCl (1 M in MeOH, 3.0 mL) 
and Pd/C (10% w/w, 200 mg, 0.2 mmol) and stirred under 1 atm. H2 for 18 h at RT.  The suspension was 
filtered through a pad of Celite, rinsed with MeOH, and the filtrates conc. in vacuo.  CH2Cl2 (5.0 mL) was 
added and conc. in vacuo to give 14.HCl (212 mg, 57%). Compound 14 can also be ‘free based’: A solution 
of rel-(3aS,7aR)-hexahydrooxazolo[5,4-c]pyridin-2(1H)-one hydrochloride (14.HCl) in MeOH was treated 
with solid supported NaHCO3 for 10 min before being filtered and concentrated in vacuo. 
 
4.6.1 Compound 14.HCl 
A sand coloured solid which was used without further purification. M.p. 155 °C (dec.); IR cm-1 3012, 
2962, 2930, 2361, 2338, 1717; 1H NMR (400 MHz, DMSO-d6) δ 9.58 (1H, br s, NH), 8.89 (1H, br s, NH), 4.74 
(1H, d app. t, J = 7.3 and 2.9 Hz, H-7), 3.92 (1H, app. dd, J = 12.7 and 6.3 Hz, H-2), 3.44-3.24 (2H, m, H-4), 
3.08-2.91 (2H, m, H-6), 2.07-1.99 (1H, m, H-3), 1.65-1.57 (1H, m, H-3); 13C NMR (100 MHz, DMSO-d6) δ 
158.2 (CO), 70.3 (C-7), 47.1 (C-6), 41.6, 38.1, 25.1 (C-3); HRMS m/z calculated for C6H1N2O2: 143.0815 
[M+H]+, found: 143.0817.  
 
4.7 Procedure for the synthesis of compound 15 
To a solution of 12f (400 mg, 1.5 mmol) in MeOH (15.0 mL) was added HCl (1 M in MeOH, 3.0 mL) 
and Pd/C (10%, 160 mg, 0.15 mmol) and stirred under 1 atm. H2 for 18 h at RT.  The suspension was filtered 
through a pad of Celite, rinsed with MeOH, and the filtrates conc. in vacuo.  CH2Cl2 (5.0 mL) was added and 
conc. in vacuo to give 15 (121 mg, 38%). 
 
4.7.1 Compound 15 
 A brown coloured solid which was used without further purification.  M.p. 130 °C (dec.); IR cm-1 
3011, 2361, 2341, 1759; 1H NMR (400 MHz, DMSO-d6) δ 9.81 (1H, br s, NH), 9.10 (1H, br s, NH), 4.77 (1H, 
d app. t, J = 6.2 and 3.5 Hz, H-7), 4.07 (1H, app. dd, J = 12.6 and 6.2 Hz, H-2), 3.31-3.38 (3H, m, H-6 and 
CHHCH3, under water peak, observed by COSY), 3.13-2.98 (3H, 3.13-2.98, m, H-4 and CHHCH3), 2.21-2.13 
(1H, m, H-4), 1.78-1.70 (1H, m, H-3), 1.12 (3H, t, J = 7.2 Hz, CH3); 13C NMR (101 MHz, DMSO-d6) δ 156.8 
(CO), 68.8 (C-7), 50.1 (C-2), 41.2 (C-6), 37.8 (C-4), 36.6 (CH2CH3), 22.0 (C-3), 13.2 (CH3); HRMS m/z 
calculated for C8H15N2O2: 171.1128 [M+H]+, found: 171.1126. 
 
4.8 General Procedure C: HATU-mediated amide coupling 
A solution of the appropriate amine (1 mol. equiv.) in DMF (10.0 mL/mmol) was added to the 
appropriate carboxylic acid (1.2 mol. equiv.), followed by DIPEA (4 mol. equiv.) and a solution of HATU (1.2 
mol. equiv.) in DMF (5.0 mL/mmol) and shaken at RT overnight. 
 
4.8.1 Compound 12g 
Compound 12g was prepared according to the general procedure (4.8): 14.HCl (22 mg, 0.1 mmol), 
DMF (1.0 mL), 2-(fluorophenoxy)nicotinic acid (28 mg, 0.12 mmol), DIPEA (70 μL, 0.4 mmol) and HATU 
(46 mg, 0.12 mmol) in DMF (0.5 mL).  Purification (prep. HPLC) gave 12g (7 mg, 27%) as a beige coloured 
solid. M.p. 210-212 °C; IR cm-1 3674, 3033, 1769, 1635, 1602, 1504, 1421; 1H NMR (400 MHz, DMSO-d6, 
363 K) δ 8.18 (1H, dd, J = 4.9 and 1.9 Hz, H-6), 7.75 (1H, dd, J = 7.3 and 1.9 Hz, H-8), 7.31 (1H, br s, NH), 7.21 
(1H, dd, J = 7.3 and 4.9 Hz, H-7), 7.19-7.17 (4H, m, H-9 and H-10), 4.81-4.68 (1H, m, H-5), 4.08-4.06 (1H, m, 
H-1), 3.76-3.26 (4H, m, H-4 and H-3), 2.05-1.70 (2H, m, H-2); HRMS m/z calculated for C18H16FN3O4: 
358.1198 [M+H]+, found: 358.1196. 
 
4.8.2 Compound 12h 
Compound 12h was prepared according to the general procedure (4.8): 15 (21 mg, 0.1 mmol), DMF 
(1.0 mL), 2-(fluorophenoxy)nicotinic acid (28 mg, 0.12 mmol), DIPEA (70 μL, 0.4 mmol) and HATU (46 mg, 
0.12 mmol) in DMF (0.5 mL).  Purification (prep. HPLC) gave 12h (21 mg, 67%) as a beige solid. M.p. 117-
118 °C; IR cm-1 3691, 3005, 1752, 1634; 1H NMR (400 MHz, DMSO-d6, 363 K) δ 8.18 (1H, dd, J = 4.9 and 1.9 
Hz, H-6), 7.74 (1H, dd, J = 7.3 and 1.9 Hz, H-8), 7.21 (1H, dd, J = 7.3 and 4.9 Hz, H-7), 7.19-7.17 (4H, m, H-9 
and H-10), 4.75-4.65 (1H, m, H-5), 4.13-4.09 (1H, m, H-1), 3.66-3.49 (2H, m, H-4), 3.12-2.98 (4H, m, H-3 
and CH2CH3), 2.10-1.86 (2H, m, H-2), 1.14-1.08 (3H, m, CH3); 13C NMR (101 MHz, DMSO-d6) δ 166.3 (CO 
amide), 156.5 (CO carbamate), 149.2 (C-Ar), 147.8 (C-6), 123.6 (C-Ar), 123.5 (C-Ar), 123.3 (C-Ar), 121.0 (C-
Ar), 120.8 (C-Ar), 120.2 (C-Ar), 119.2 (C-Ar), 116.1 (c-Ar), 115.9 (C-Ar), 70.8 (C-5), 50.0 (C-1), 44.5 (C-4), 
37.3 (C-3), 36.0 (CH2CH3), 22.5 (C-2), 12.4 (CH3); HRMS m/z calculated for  C20H20FN3O4 [m+H]+: 386.1511, 
found: 386.1511. 
 
4.8.3 Compound 12i 
Compound 12i was prepared according to the general procedure (4.8): 14.HCl (22 mg, 0.1 mmol), 
DMF (1.0 mL), 2-(fluorophenoxy)nicotinic acid (28 mg, 0.12 mmol), DIPEA (70 μL, 0.4 mmol) and HATU 
(46 mg, 0.12 mmol) in DMF (0.5 mL).  Purification (prep. HPLC) gave 12i (8 mg, 30%) as a yellow sticky 
solid. IR cm-1 3692, 3461, 3011, 1767, 1714, 1637, 1608, 1433; 1H NMR (400 MHz, DMSO-d6, 363 K) δ 7.80 
(2H, d, J = 7.5 Hz, H-Ar), 7,67-7.58 (3H, m, H-Ar), 7.42-7.38 (1H, m, H-Ar), 7.34-7.12 (2H, m, H-Ar and NH), 
4.87-4.56 (1H, m, H-5), 4.10-4.01 (1H, m, H-1), 3.77-3.54 (2H, m, H-4), 3.42-3.12 (2H, m, H-3), 2.07-1.81 
(2H, m, H-2); 13C NMR (101 MHz, DMSO-d6) δ 191.9 (CO ketone), 167.3 (CO amide), 159.0 (CO carbamate), 
143.8 (C-Ar), 143.4 (C-Ar), 135.7 (C-Ar), 135.4 (C-Ar), 134.1 (C-Ar), 132.9 (C-Ar), 129.8 (C-Ar), 128.6 (C-
Ar), 127.7 (C-Ar), 124.0 (C-Ar), 121.4 (C-Ar), 72.8 (C-5), 47.5 (C-1), 44.2 (C-3), 36.7 (C-4), 23.6 (C-2); HRMS 
m/z calculated for C20H16N2O4: 349.1183 [M+H]+, found: 349.1181. 
 4.8.3 Compound 12j 
Compound 12j was prepared according to the general procedure (4.8): 15 (21 mg, 0.1 mmol), DMF 
(1.0 mL), 2-(fluorophenoxy)nicotinic acid (28 mg, 0.12 mmol), DIPEA (70 μL, 0.4 mmol) and HATU (46 mg, 
0.12 mmol) in DMF (0.5 mL).  Purification (prep. HPLC) gave 12j (13.2 mg, 47%) as an orange coloured 
solid. M.p. 201-203 °C; IR cm-1 3691, 3007, 1751, 1714, 1635; 1H NMR (400 MHz, DMSO-d6, 363 K) δ 7.82-
7.79 (2H, m, H-Ar), 7.67-7.58 (3H, m, H-Ar), 7.42-7.38 (1H, m, H-Ar), 7.17-7.10 (1H, m, H-Ar), 4.82-4.53 (1H, 
m, H-5), 4.14-4.03 (1H, m, H-1), 3.68-3.02 (6H, m, H-4, H-3 and CH2CH3), 2.13-1.85 (2H, m, H-2), 1.15-1.04 
(3H, m, CH3); 13C NMR (101 MHz, DMSO-d6) δ 191.3 (CO ketone), 167.3 (CO amide), 156.5 (CO carbamate), 
143.8 (C-Ar), 143.4 (C-Ar), 135.7 (C-Ar), 135.5 (C-Ar), 134.1 (C-Ar), 132.9 (C-Ar), 129.8 (C-Ar), 128.7 (C-
Ar), 127.6 (C-Ar), 123.9 (C-Ar), 121.5 (C-Ar), 121.4 (C-Ar), 70.8 (C-5), 50.1 (C-1), 44.2, 37.0, 36.0, 20.6 (C-
2), 12.4 (CH3); HRMS m/z calculated for C22H20N2O4: 399.1315 [M+H]+, found: 399.1324. 
 
4.9 Procedure for the synthesis of compound 12k 
A solution of 14 (14 mg, 0.1 mmol) in NMP (1.0 mL) was added to benzofuran-2-carbaldehyde (18 
mg, 0.12 mmol), followed by AcOH (11 μL, 0.2 mmol) and a solution of sodium triacetoxyborohydride (53 
mg, 0.2 mmol) in NMP (0.5 mL) and shaken at RT overnight.  Purification (prep. HPLC) gave 12k (11 mg, 
55%). 
 
4.9.1 Compound 12k 
 A yellow coloured sticky solid. IR cm-1 3691, 3448, 3007, 2955, 2824, 2784, 1761, 1603, 1455; 1H 
NMR (400 MHz, DMSO-d6) δ 7.60-7.54 (3H, m, H-7, H-10 and NH), 7.29-7.20 (2H, m, H-8 and H-9), 6.79 (1H, 
s, H-6), 4.50 (1H, dd, J = 11.6 and 5.4 Hz, H-5), 3.76-3.73 (3H, m, H-1 and H-benzylic), 2.74 (1H, dd, J = 12.6 
and 4.9 Hz, H-4), 2.63 (1H, dd, J = 12.6 and 5.4 Hz, H-4), 2.49-2.46 (1H, m, H-3), 2.35-2.29 (1H, m, H-3), 1.88-
1.80 (1H, m, H-2), 1.62-1.54 (1H, m, H-2); 13C NMR (101 MHz, CDCl3) δ 159.7 (CO), 155.1 (C-Ar), 153.8 (C-
Ar), 128.2 (C-Ar), 124.1 (C-9), 122.8 (C-8), 120.9 (C-7), 111.3 (C-10), 106.0 (C-6), 73.8 (C-5), 54.9 (C-
benzylic), 53.5 (C-4), 49.8 (C-1), 47.7 (C-3), 28.0 (C-2); HRMS m/z calculated for C15H16N2O3: 273.1234 
[M+H]+, found: 273.1228. 
 
4.10 Procedure for the synthesis of compound 12l 
A solution of 14 (14 mg, 0.1 mmol) in NMP (1.0 mL) was added to 3-(pyridine-4-yl)benzaldehyde 
(22 mg, 0.12 mmol), followed by AcOH (11 μL, 0.2 mmol) and a solution of sodium triacetoxyborohydride 
(53 mg, 0.2 mmol) in NMP (0.5 mL) and shaken at RT overnight.  Purification (prep. HPLC) gave 12l (15 
mg, 67%). 
 
4.10.1 Compound 12l 
 A yellow coloured sticky solid. IR cm-1 3693, 3448, 3000, 1760, 1702, 1598; 1H NMR (400 MHz, 
DMSO-d6) δ 8.70-8.69 (1H, m, H-Ar), 8.64-8.62 (2H, m, H-Ar), 7.81-7.80 (1H, m, H-Ar), 7.71-7.69 (2H, m, H-
Ar), 7.51-7.47 (1H, m, H-Ar), 7.42-7.39 (1H, m, H-Ar), 4.50 (1H, app. dd, J = 11.8 and 5.3 Hz, H-5), 3.77 (1H, 
dd, J = 11.8 and 5.9 Hz, H-1), 3.60 (2H, s, H-benzylic), 2.65 (1H, dd, J = 12.7 and 4.9 Hz, H-4), 2.58 (1H, dd, J 
= 12.7 and 5.3 Hz, H-4), 2.46-2.40 (1H, m, H-3), 2.27-2.21 (1H, m, H-3), 1.88-1.80 (1H, m, H-2), 1.63-1.55 
(1H, m, H-2) ; 13C NMR (101 MHz, DMSO-d6) δ 158.9 (CO), 154.8 (C-Ar), 154.3 (C-Ar), 128.0 (C-Ar), 123.9 
(C-Ar), 122.7 (C-Ar), 120.8 (C-Ar), 111.0 (C-Ar), 105.4 (C-Ar), 72.9 (C-5), 53.8 (C-benzylic), 53.0 (C-4), 48.7 
(C-1), 47.4 (C-3), 28.1 (C-2); HRMS m/z calculated for C18H19N3O2: 310.1550 [M+H]+, found: 310.1547. 
 
4.11 Procedure for the synthesis of compound 7a 
A solution of 3,4-epoxycyclopent-1-ene (0.50 g, 6.09 mmol) in freshly distilled THF (50 mL) was 
cooled to 0 °C under Ar. Tris(dibenzylideneacetone)dipalladium(0) chloroform adduct ((dba)3Pd2.CHCl3) 
(0.06 g, 0.06 mmol) was then added followed by the addition of triisopropyl phosphite (0.16 mL, 0.73 
mmol) and p-methoxybenzyl isocyanate (0.87 mL, 0.01 mmol). The yellow reaction mixture was stirred for 
18 h at RT and concentrated in vacuo. Purification by column chromatography over silica gel (eluting with 
1:3-1:1 EtOAc/petrol) gave 7a (0.90 g, 64 %). 
 
4.11.1 Compound 7a 
 Yellow needle like crystals. M.p. 96.8-97.0 (EtOAc/hexane). IR cm-1 (nujol; cm-1) 1720 (C=O); 1H 
NMR (400MHz, CDCl3) 7.46 (2H, m, Ar), 6.92 (2H, m, Ar), 6.05-6.00 (1H, m, H-3), 5.91-5.89 (1H, m, H-2), 
5.22-5.12 (2H, m, H1 and H-5), 3.80 (3H, s, CH3), 2.90-2.79 (2H, m, H-4); 13C NMR (100 MHz, CDCl3) 156.9 
(C=O), 155.0 (Ar), 154.0 (Ar), 134.1 (C-2), 127.6 (Ar), 122.2 (C-3), 114.6 (Ar), 75.5 (C-1), 67.4 (C-5), 55.7 
(CH3), 39.8 (C-4); HRMS m/z calculated for C13H14NO3: 232.0968 [M+H]+, found: 232.0972. 
 
4.12 Procedure for the synthesis of compound 7b 
A solution of 3,4-epoxycyclopent-1-ene (1.0 g, 0.01 mol) in freshly distilled THF (50 mL) was cooled 
to 0 °C under Ar. Tris(dibenzylideneacetone)dipalladium(0) chloroform adduct ((dba)3Pd2.CHCl3) (0.13 g, 
0.12 mmol) was then added followed by the addition of triisopropyl phosphite (0.17 mL, 0.72 mmol) and 
p-toluenesulfonyl isocyanate (2.0 mL, 0.01 mol). The resulting yellow reaction mixture was stirred for 18 
h at RT and concentrated in vacuo. Purification by column chromatography over silica gel (eluting with 1:4-
1:1 EtOAc/petrol.) to give 7b (1.2 g, 36%). 
 
4.12.1 Compound 7b17 
A white crystalline solid. 1H NMR (400MHz, CDCl3) 7.96 (2H, m, Ar), 7.36 (2H, m, Ar), 6.06-5.98 (2H, 
m, H-3 and H-3), 5.31-5.27 (1H, m, H-1), 5.14-5.10 (H, m, H-5), 2.86-2.66 (2H, m, H-4), 2.45 (3H, s, CH3). 
 
4.13 Procedure for the synthesis of compound 7c 
A solution of 7a (0.46 g, 1.99 mmol) in MeCN (7.0 mL) was cooled to 0 °C. An aqueous solution of 
ammonium cerium(IV) nitrate (1.64 g, 2.98 mmol, 7.0 mL of water) was then added. The reaction mixture 
was stirred for 2 h at RT and then concentrated in vacuo. The resulting solution was diluted with water (50 
mL), extracted with EtOAc (3x100 mL), dried over MgSO4 and conc. in vacuo. Purification by column 
chromatography over activity IV alumina (eluting with 3:1-1:1 petrol/EtOAc) gave 7c (0.16 g, 63%) as a 
yellow oil. Alternatively: A solution of naphthalene (0.50 g, 3.90 mmol) in dry DME (20 mL) under argon 
was stirred at room temperature. Sodium (0.30 g, 0.01 mol) was then added in small portions and the 
resulting green solution was stirred for 18 h at RT. A solution of 7b (0.20 g, 0.72 mmol) in THF (20 mL) 
was cooled to -78 °C under argon and the reducing solution was transferred via a cannula until the reaction 
mixture turned green. The resulting solution was stirred for another 18 h at RT. Water (50 mL) was then 
added and the organic layer was separated. The aqueous layer was extracted with EtOAc (3x50 mL). The 
combined organic layers were washed with brine, dried and conc. in vacuo. Purification by column 
chromatography over activity IV alumina (eluting with 1:1 hexane/EtOAc) gave 7c (0.01 g, 11%). 
 
4.13.1 Compound 7c18 
 A yellow oil. 1H NMR (400MHz, CDCl3) 6.90 (1H, br s, NH), 5.94-5.90 (1H, m, H-3), 5.76-5.72 (1H, m, 
H-2), 5.24-5.18 (1H, m, H-5), 4.73-4.68 (1H, m, H-1), 2.84-2.68 (2H, m, H-4).  
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